August 23, 2011 — PLC Systems Inc. said the final results from the REMEDIAL II investigator-sponsored clinical trial have been published online in Circulation, a peer-reviewed journal of the American Heart Association. It will appear in the September 2011 issue of the publication. REMEDIAL II is an Italian trial of the company’s RenalGuard device.

August 23, 2011 — nContact Inc. has received CE Mark approval for the EPi-Sense Guided Coagulation Device with VisiTrax for the treatment of cardiac arrhythmias, including atrial fibrillation (AF). The EPi-Sense features epicardial sensing electrodes designed to allow both electrophysiologists (EP) and cardiothoracic surgeons to map and navigate the epicardium and locate areas for linear epicardial ablation.

August 23, 2011— UltraSPECT of Haifa, Israel, announced the sale of more than 10 of its wide beam reconstruction (WBR) software solutions to nuclear pharmaceutical supplier PCI for placement at customer medical facilities throughout Arizona. PCI is a member of United Pharmacy Partners Inc. (UPPI), a nuclear pharmacy network consortium that recently signed a multi-year distribution agreement for the leasing and/or non-exclusive sales of UltraSPECT’s cardiac and bone imaging applications in the United States.

August 23, 2011 — Cardium Therapeutics received the final $1.1 million payment from Royal Philips Electronics in connection with Philips' acquisition of Innercool Therapies from Cardium. The purchase gives Philips Healthcare a therapeutic hypothermia product line for use in heart attack, sudden cardiac arrest and neuro trauma patients

August 19, 2011 - Neovasc Inc. accomplished $4.7 million in financing to complete the COSIRA clinical trial for the Neovasc Reducer to treat refractory angina. The company will also advance the Tiara project to develop a transcatheter device to treat the mitral valve regurgitation.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now